OSAplex MK-7 60 Pkt.

OSAplex MK-7 60 Packets by Xymogen

OSAplex MK-7 by Xymogen is a complete, easy-to-use bone joint and muscle support supplement with multiple potential, beneficial effects.* Each packet contains two capsules with a blend of microcrystalline hydroxyapatite concentrate (MCHC) from Ossopan 1100™, vitamin D3, and vitamin K2, along with one capsule of choline-stabilized orthosilicic acid (ch-OSA®‡).* As such, this product can provide essential nutrients and vitamins that your bones and muscles may need.*

Who Should Consider OSAplex MK-7 60 Pkt by Xymogen?

OSAplex MK-7 60 pkt may support your health if you:

• do not consume sufficient amounts of vitamins D3 and K2 in your diet*
• want to improve your bone strength and density*
• look for a complex supplement that provides multiple essential nutrients*

How May OSAplex MK-7 60 Pkt Support Your Health?

OSAplex MK-7 60 Pkt may:

• support bone strength and mineral density*
• promote bone collagen formation*
• help you maintain bone health by providing your body with multiple nutrient*

Supplements support your health but do not replace a balanced diet. Always check with your healthcare practitioner if you have doubts about a new supplement. Book a FREE product consultation to learn more about OSAplex MK-7 60 Pkt.

Recommendation:
Xymogen suggests consuming the contents of one OSAplex MK-7 packet daily, or as directed by your healthcare practitioner.
*Each packet contains: 2 ActivNutrients without Iron capsules, 1 Oraxinol capsule, 1 OmegaPure 600 EC softgel.*

Serving Size: 1 Packet
Servings Per Container: 60

Amount Per Serving:

MICROCRYSTALLINE HYDROXYAPATITE CONCENTRATE WITH VITAMIN D3 AND K2 CAPSULES:
Vitamin D3 (cholecalciferol) 25 mcg (1000 IU)
Calcium (as MCHC)S2 550 mg
Phosphorus (as MCHC)S2 198 mg
MCHC S2 2.2 g 
Microcrystalline Hydroxyapatite (as MCHC)S2 1.32 g 
Vitamin K2 (as menaquinone-7) 45 mcg

Other Ingredients for MICROCRYSTALLINE HYDROXYAPATITE CONCENTRATE WITH VITAMIN D3 AND K2 CAPSULES:
Capsule (hypromellose and water), vegetable stearic acid, vegetable magnesium stearate, medium-chain triglyceride oil, and silica.

CHOLINE-STABILIZED ORTHOSILICIC ACID CAPSULE:
Choline (as choline-stabilized orthosilicic acid)^S1 60 mg
Silicon (as choline-stabilized orthosilicic acid)^S1 3 mg

Other Ingredients for CHOLINE-STABILIZED ORTHOSILICIC ACID CAPSULE:
Microcrystalline cellulose, capsule (hypromellose and water), and purified water.

Does Not Contain: Wheat, gluten, yeast, soy protein, dairy products, fish, shellfish, peanuts, tree nuts, egg, sesame, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, and artificial preservatives.

Caution:
Consult your healthcare professional prior to use. Individuals taking medication should discuss potential interactions with their healthcare professional. Consider total vitamin K intake (food + supplements) if you are taking blood-thinning medication. Do not use if packet is damaged.

*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Storage:
Keep tightly closed in a cool, dry place out of reach of children.

Click here to view Data Sheet

LEGAL NOTICE: Xymogen's Exclusive Professional Formulas are available through select licensed health care professionals. The Internet Sale and Discounting of XYMOGEN formulas are strictly prohibited. covenanthealthproducts.com makes XYMOGEN formulas available only to patients of our clinic. If you are a patient of covenanthealthproducts.com, you may inquire about XYMOGEN by calling (800) 627-6518

References:

1. Albertazzi, P., Steel, S. A., Howarth, E. M., et al. (2004). Comparison of the effects of two different types of calcium supplementation on markers of bone metabolism in a postmenopausal osteopenic population with low calcium intake: A double-blind placebo-controlled trial. Climacteric, 7(1), 33–40. [PMID: 15259281]
2. Bischoff-Ferrari, H. A., Willett, W. C., Orav, E. J., et al. (2012). A pooled analysis of vitamin D dose requirements for fracture prevention. New England Journal of Medicine, 367(1), 40–49. [PMID: 22762317]
3. Blair, H. C., Robinson, L. J., Huang, C. L., et al. (2011). Calcium and bone disease. Biofactors, 37(3), 159–167. [PMID: 21674636]
4. Calomme, M. R., Geusens, P., Demeester, N., et al. (2006). Partial prevention of long-term femoral bone loss in aged ovariectomized rats supplemented with choline-stabilized orthosilicic acid. Calcified Tissue International, 78(4), 227–232. [PMID: 16604283]
5. Calomme, M. R., & Vanden Berghe, D. A. (1997). Supplementation of calves with stabilized orthosilicic acid. Effect on the Si, Ca, Mg, and P concentrations in serum and the collagen concentration in skin and cartilage. Biological Trace Element Research, 56(2), 153–165. [PMID: 9164661]
6. Castelo-Branco, C., Ciria-Recasens, M., Cancelo-Hidalgo, M. J., et al. (2009). Efficacy of ossein-hydroxyapatite complex compared with calcium carbonate to prevent bone loss: A meta-analysis. Menopause, 16(5), 984–991. [PMID: 19407667]
7. Castelo-Branco, C., Pons, F., Vicente, J. J., et al. (1999). Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds. Results of a two-year, prospective trial. Journal of Reproductive Medicine, 44(7), 601–605. [PMID: 10442322]
8. Gaby, A. (2011). Nutritional medicine. Concord, NH: Fritz Perlberg Publishing.
9. Jugdaohsingh, R. (2007). Silicon and bone health. Journal of Nutrition Health and Aging, 11(2), 99–110. [PMID: 17435952]
10. Kärkkäinen, M., Tuppurainen, M., Salovaara, K., et al. (2010). Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65–71 years: A 3-year randomized population-based trial (OSTPRE-FPS). Osteoporosis International, 21(12), 2047–2055. [PMID: 20204604]
11. Knapen, M. H., Drummen, N. E., Smit, E., et al. (2013). Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporosis International. [Epub ahead of print]. [PMID: 23525894]
12. Lips, P., & van Schoor, N. M. (2011). The effect of vitamin D on bone and osteoporosis. Best Practice & Research Clinical Endocrinology & Metabolism, 25(4), 585–591. [PMID: 21872800]
13. Pelayo, I., Haya, J., De la Cruz, J. J., et al. (2008). Raloxifene plus ossein-hydroxyapatite compound versus raloxifene plus calcium carbonate to control bone loss in postmenopausal women: A randomized trial. Menopause, 15(6), 1132–1138. [PMID: 18791486]
14. Reffitt, D. M., Ogston, N., Jugdaohsingh, R., et al. (2003). Orthosilicic acid stimulates collagen type 1 synthesis and osteoblastic differentiation in human osteoblast-like cells in vitro. Bone, 32(2), 127–135. [PMID: 12633784]
15. Rüegsegger, P., Keller, A., & Dambacher, M. A. (1995). Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females. Osteoporosis International, 5(1), 30–34. [PMID: 7703621]
16. Schurgers, L. J., Teunissen, K. J., Hamulyák, K., et al. (2007). Vitamin K-containing dietary supplements: Comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood, 109(8), 3279–3283. [PMID: 17158229]
17. Shearer, M. J. (1997). The roles of vitamins D and K in bone health and osteoporosis prevention. Proceedings of the Nutrition Society, 56(3), 915–937. [PMID: 9483660]
18. Spector, T. D., Calomme, M. R., Anderson, S. H., et al. (2008). Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: A randomized, placebo-controlled trial. BMC Musculoskeletal Disorders, 9, 85. [PMID: 18547426]
19. Silica. (2013). Natural Standard Database. Retrieved June 12, 2013, from http://www.naturalstandard.com/databases/herbssupplements/silica.asp?#
20. Viguet-Carrin, S., Garnero, P., & Delmas, P. D. (2006). The role of collagen in bone strength. Osteoporosis International, 17(3), 319–336. [PMID: 16341622]
21. Weber, P. (1997). Management of osteoporosis: Is there a role for vitamin K? International Journal for Vitamin and Nutrition Research, 67(5), 350–356. [PMID: 9350477]